![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
![[thumbnail of 10591oa.pdf]](https://edoc.mdc-berlin.de/style/images/fileicons/application_pdf.png) |
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
248kB |
| Item Type: | Review |
|---|---|
| Title: | Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases |
| Creators Name: | Smink, J.J. and Leutz, A. |
| Abstract: | Lytic bone diseases and in particular osteoporosis are common age-related diseases characterized by enhanced bone fragility due to loss of bone density. Increasingly, osteoporosis poses a major global health-care problem due to the growth of the elderly population. Recently, it was found that the gene regulatory transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta) is involved in bone metabolism. C/EBPbeta occurs as different protein isoforms of variable amino terminal length, and regulation of the C/EBPbeta isoform ratio balance was found to represent an important factor in osteoclast differentiation and bone homeostasis. Interestingly, adjustment of the C/EBPbeta isoform ratio by the process of translational control is downstream of the mammalian target of rapamycin kinase (mTOR), a sensor of the nutritional status and a target of immunosuppressive and anticancer drugs. The findings imply that modulating the process of translational control of C/EBPbeta isoform expression could represent a novel therapeutic approach in osteolytic bone diseases, including cancer and infection-induced bone loss. |
| Keywords: | C/EBPbeta, MafB, Osteoporosis, Rapamycin, Cancer, Leukemia, Animals |
| Source: | Journal of Molecular Medicine |
| ISSN: | 0946-2716 |
| Publisher: | Springer |
| Volume: | 88 |
| Number: | 3 |
| Page Range: | 227-233 |
| Date: | March 2010 |
| Official Publication: | https://doi.org/10.1007/s00109-009-0567-8 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
